AcelRx Pharmaceuticals

AcelRx Pharmaceuticals Current Liabilities

Delisted

The Current Liabilities of AcelRx Pharmaceuticals (ACRX) as of Oct 24, 2026 is 4.51 M USD. In the previous year, Current Liabilities was 25.36 M USD — a change of -82.20% (lower).

Current Liabilities

4.51 MUSD

YoY

-82.20%

Last updated:

Current Liabilities of AcelRx Pharmaceuticals is 2023 4.51 M USD. Current Liabilities of AcelRx Pharmaceuticals was 2022 25.36 M USD. It decreases by -82.20% lower compared to the previous year.

The AcelRx Pharmaceuticals Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2016
18.13 M USD
Jan 1, 2017
25.10 M USD
Jan 1, 2018
29.11 M USD
Jan 1, 2019
24.70 M USD
Jan 1, 2020
32.39 M USD
Jan 1, 2021
34.72 M USD
Jan 1, 2022
25.36 M USD
Jan 1, 2023
4.51 M USD
The AcelRx Pharmaceuticals Current Liabilities history
YEARCurrent LiabilitiesYoY
4.51 MUSD-82.20%
25.36 MUSD-26.98%
34.72 MUSD+7.22%
32.39 MUSD+31.12%
24.70 MUSD-15.16%
29.11 MUSD+16.00%
25.10 MUSD+38.44%
18.13 MUSD-3.96%
18.88 MUSD-19.83%
23.54 MUSD+132.07%
10.15 MUSD-61.62%
26.43 MUSD+86.86%
14.15 MUSD-27.50%
19.51 MUSD+75.58%
11.11 MUSD+41.92%
7.83 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AcelRx Pharmaceuticals Stock analysis

What does AcelRx Pharmaceuticals do? AcelRx Pharmaceuticals Inc. is a California-based company specializing in the manufacturing of pain relief medications. The company was founded in 2005 and has since become an innovator in the development of pain medications. AcelRx's business model involves selling its patented products to hospitals and other healthcare facilities, and it is currently expanding into the global market. The company focuses on developing pain medications for emergency medicine and palliative care, with a particular emphasis on delivering medications through sprays or injections for fast-acting relief. AcelRx offers products such as Zalviso, a pain reliever based on Fentanyl nasal sprays used for post-operative pain, and Dsuvia, a sublingual tablet containing the active ingredient Sufentanil for severe pain. The FDA has approved Dsuvia as safe and effective. AcelRx has also entered partnerships with other pharmaceutical companies, such as Grünenthal and Chinese company R-Pharm, to bring its products to the international market. The company is committed to investing in research and development for innovative pain relief solutions, including a new research program targeting the development of medications for neuropathic pain. AcelRx Pharmaceuticals is a positive example of how modern pharmaceuticals can improve healthcare and quality of life. The company has demonstrated its potential through dedication and continuous research and development, and it is likely to make even greater contributions in the future. AcelRx Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AcelRx Pharmaceuticals stock

Current Liabilities of AcelRx Pharmaceuticals is 4.51 M USD in 2023.

Current Liabilities of AcelRx Pharmaceuticals changed from 25.36 M USD to 4.51 M USD, representing a -82.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities AcelRx Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's AcelRx Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — AcelRx Pharmaceuticals

All Key Metrics — AcelRx Pharmaceuticals